CD4+CD25+ Regulatory T-Cell Frequency in HER-2/neu (HER)-Positive and HER-Negative Advanced-Stage Breast Cancer Patients

• Published in: Clinical cancer research 2007-05, Vol.13 (9), p.2714-2721
• Main Authors: PEREZ, Sonia A, KARAMOUZIS, Michael V, PAPAMICHAIL, Michael, SKARLOS, Dimosthenes V, ARDAVANIS, Alexandros, SOTIRIADOU, Nectaria N, LLIOPOULOU, Eleni G, SALAGIANNI, Maria L, ORPHANOS, George, BAXEVANIS, Constantin N, RIGATOS, Gerasimos
• Format: Article
• Language: English
• Subjects: Antibodies, Monoclonal - therapeutic use; Antibodies, Monoclonal, Humanized; antibody therapy; Antineoplastic agents; Antineoplastic Agents - therapeutic use; Biological and medical sciences; breast cancer; Breast Neoplasms - drug therapy; Breast Neoplasms - immunology; Breast Neoplasms - pathology; CD4 Antigens - analysis; Female; Gynecology. Andrology. Obstetrics; HER-2; Humans; Interleukin-2 Receptor alpha Subunit - analysis; Lymphocyte Count; Mammary gland diseases; Medical sciences; Neoplasm Staging; neu; Pharmacology. Drug treatments; Prognosis; Receptor, ErbB-2 - analysis; regulatory T cells; T-Lymphocytes, Regulatory - immunology; Trastuzumab; Treatment Outcome; Tumors
• ISSN: 1078-0432; 1557-3265
• DOI: 10.1158/1078-0432.CCR-06-2347

Purpose: CD4 + CD25 bright regulatory T cells (Tregs) are increased in patients with several malignancies and correlate with disease stage and prognosis. Breast cancer patients represent a heterogeneous population with unpredictable disease progression even at advanced stages. Circulating Tregs in correlation with HER-2/ neu (HER) status and treatment with chemotherapy, either alone or in combination with trastuzumab therapy, were monitored in advanced-stage breast cancer patients. Experimental Design: Circulating Treg frequency and absolute counts of 46 HER + and 28 HER − , stage III and IV, breast cancer patients before therapy and during trastuzumab therapy and/or chemotherapy have been compared with 24 healthy donors and correlated with plasma HER extracellular domain concentration and clinical outcome. Results: Treg frequency in HER + patients was significantly increased compared with both HER − patients and healthy donors. Trastuzumab therapy, with or without combined chemotherapy, resulted in a progressive decrease of circulating Tregs. Percentage change in Tregs statistically correlated with percentage change in plasma HER extracellular domain. Furthermore, decrease in Tregs correlated with either objective clinical response or stable disease, whereas increased Treg frequency during trastuzumab therapy coincided with disease progression. No statistically significant change in Treg frequency following chemotherapy was observed in HER − patients. Conclusions: Treg cell frequency does not directly correlate with clinical stage in breast cancer, as stage III and IV HER + and HER − patients exhibit significantly different Treg profiles. Trastuzumab therapy, either alone or combined with chemotherapy, results in decreased Treg frequency in HER + advanced patients with an objective clinical response.